Lenvatinib: all 359 studies that test it
Page 3 of 4. Open to participants first (137), then studies with results posted, then the rest; newest registration first within each.
- Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the LungCompletedNCT01877083Phase 2Results posted
- A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular CarcinomaCompletedNCT01761266Phase 3Results posted
- A Study of E7080 in Subjects With Advanced Thyroid CancerCompletedNCT01728623Phase 2Results posted
- A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different TreatmentsCompletedNCT01529112Phase 2Results posted
- A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)TerminatedNCT01433991Phase 1/2Results posted
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)CompletedNCT01321554Phase 3Results posted
- A Study of E7080 in Subjects With Solid TumorCompletedNCT01268293Phase 1Results posted
- An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV MelanomaCompletedNCT01136967Phase 2Results posted
- A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted TreatmentCompletedNCT01136733Phase 1/2Results posted
- E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV MelanomaCompletedNCT01133977Phase 1/2Results posted
- E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125TerminatedNCT01133756Phase 1/2Results posted
- Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease ProgressionCompletedNCT01111461Phase 2Results posted
- Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC)CompletedNCT00946153Phase 1/2Results posted
- E7080 in Combination With Carboplatin and Paclitaxel in Patients With Non-small Cell Lung Cancer (NSCLC)CompletedNCT00832819Phase 1Results posted
- Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by HistologyCompletedNCT00784303Phase 2Results posted
- An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid TumorsCompletedNCT00280397Phase 1Results posted
- An Open Label Dose Escalation Study Of E7080CompletedNCT00121719Phase 1Results posted
- Efficacy and Safety Comparison Between PD-1 Inhibitor Combined With Lenvatinib or With Regorafenib For UHCC After Failure of First-line TreatmentCompletedNCT07537985Not applicable
- Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular CarcinomaActive, not recruitingNCT07081633Phase 2
- Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain MetastasesWithdrawnNCT07011849Phase 2
- Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCCWithdrawnNCT06361758Phase 2
- Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural MesotheliomaActive, not recruitingNCT06318286Phase 2
- Lenvatinib After Progression on Atezolizumab-bevacizumab in Hepatocellular CarcinomaActive, not recruitingNCT06138769Phase 2
- Perioperative TORIPALIMAB Plus LENVATINIB in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PLUTO)TerminatedNCT06114940Phase 2
- A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast CancerActive, not recruitingNCT06110793Phase 1/2
- AMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C Mutant, Metastatic NSCLCWithdrawnNCT06068153Phase 2
- Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)CompletedNCT06036836Phase 2
- Lenvatinib, Pembrolizumab, and Tumor Treating Fields (TTFields) for Second-line Treatment of GlioblastomaWithdrawnNCT05973903Phase 1/2
- Lenvatinib Treatment in Waiting List of Liver Transplantation After TACE Failure in Patients With Hepatocellular CarcinomaActive, not recruitingNCT05901194Phase 1/2
- A Study to Evaluate Efficacy and Safety of Lenvatinib Combined With Tislelizumab in Patients With FHRCCCompletedNCT05877820Phase 2
- Pembrolizumab Plus Lenvatinib in Previously Treated Classic Kaposi SarcomaWithdrawnNCT05846724Phase 2
- Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial CancerActive, not recruitingNCT05824481Phase 2
- Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical CancerActive, not recruitingNCT05824468Phase 2
- Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary CancerActive, not recruitingNCT05775159Phase 2
- Efficacy and Safety Study of F520 Combined With Lenvatinib in the Treatment of Patients With Advanced Solid TumorsStatus unknownNCT05740215Phase 1/2
- Lenvatinib Plus VIC-1911 in Lenvatinib-unresponsive or Lenvatinib-resistant HCCTerminatedNCT05718882Not applicable
- Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)Active, not recruitingNCT05696548Phase 2
- HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular CarcinomaActive, not recruitingNCT05621499Not applicable
- Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior ImmunotherapyActive, not recruitingNCT05585580Phase 2
- TACE Combined With Lenvatinib and MWA in the Treatment of Locally Advanced Large Hepatocellular CarcinomaStatus unknownNCT05555316Phase 2
- Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal MelanomaWithdrawnNCT05545969Phase 2
- Lenvatinib Combined With PD-1 Inhibitors as First-line Treatment for Unresectable/Advanced Biliary Tract CarcinomaStatus unknownNCT05509478Phase 2
- Neoadjuvant Therapy of Pembrolizumab Plus Lenvatinib in Advanced RCCCompletedNCT05485896Phase 2
- Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCCActive, not recruitingNCT05433116Phase 2
- Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian CancerStatus unknownNCT05422183Phase 2
- Cryoablation Combined With Tislelizumab Plus Lenvatinib in Patients With Melanoma Liver MetastasisStatus unknownNCT05406466Phase 2
- Assessment of the Efficacy of Lenvatinib Versus Sorafenib in the Management of Advanced Hepatocellular CarcinomaStatus unknownNCT05391867Not applicable
- Pembrolizumab and Lenvatinib for Resectable Hepatocellular CarcinomaActive, not recruitingNCT05389527Phase 2
- Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung CancerActive, not recruitingNCT05384015Phase 2
- An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTCStatus unknownNCT05327582Phase 1/2
- A Phase II Study of AK104 Plus Lenvatinib and TACE in HCCActive, not recruitingNCT05319431Phase 2
- Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular CarcinomaStatus unknownNCT05312216Phase 2
- Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients with Advanced Pancreatic CancerCompletedNCT05303090Phase 1
- Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCCActive, not recruitingNCT05301842Phase 3
- Pembrolizumab and Lenvatinib in Clear Cell Ovarian CancerActive, not recruitingNCT05296512Phase 2
- Tisleizumab Combined With Lenvatinib and XELOX Regimen (Oxaliplatin Combined With Capecitabine) in the First-line Treatment of Advanced and Unresectable Biliary Tract TumorsStatus unknownNCT05291052Phase 2
- Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With LetrozoleActive, not recruitingNCT05286437Phase 2
- Radiofrequency Ablation Plus Systematic Neoadjuvant Therapy for Recurrent Hepatocellular Carcinoma (RANT Study)Status unknownNCT05277675Not applicable
- A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal AdenocarcinomaCompletedNCT05273554Phase 1
- A Study of QL1706 Plus Lenvatinib in Subjects With Advanced Renal Cell Carcinoma(RCC)Status unknownNCT05262413Phase 1/2
- Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR MutationsCompletedNCT05258279Phase 2
- Safety of XELOX Combined With GLS-010 and Lenvatinib in Advanced AFP-positive Gastric Cancer PatientsStatus unknownNCT05221775Phase 1
- TACE Combined With Lenvatinib Versus TACE Sequential Lenvatinib in the Treatment of Intermediate/Advanced Liver CancerStatus unknownNCT05220020Phase 3
- Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell CarcinomaCompletedNCT05188118Early Phase 1
- Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma PatientsCompletedNCT05171335Phase 2
- Tislelizumab（Anti PD-1), Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable, Locally Advanced Biliary Tract CancerActive, not recruitingNCT05156788Phase 2
- A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine CarcinosarcomaActive, not recruitingNCT05147558Phase 2
- Clinical Study of the Efficacy and Safety of Transhepatic Arterial Chemoembolization Combined With Tislelizumab and Lenvatinib in Patients With Advanced Unresectable Hepatocellular CarcinomaStatus unknownNCT05131698Early Phase 1
- Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer PatientsActive, not recruitingNCT05114421Phase 2
- Neoadjuvant and Adjuvant Lenvatinib in HCC Patients Treated by Percutaneous AblativeActive, not recruitingNCT05113186Phase 2
- Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver TransplantTerminatedNCT05103904Phase 2
- Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based TherapyCompletedNCT05101629Phase 2
- Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS TumorsTerminatedNCT05081180Phase 1
- A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC PatientsActive, not recruitingNCT05078931Phase 2
- Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal AdenocarcinomaActive, not recruitingNCT05041153Early Phase 1
- Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell CancerActive, not recruitingNCT05012371Phase 2
- Cryoablation Combined with Sintilimab Plus Lenvatinib in Patients with Advanced Intrahepatic CholangiocarcinomaCompletedNCT05010668Phase 2
- Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular CarcinomaCompletedNCT05003700Phase 2
- KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 AgentTerminatedNCT05001724Phase 2/3
- Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLCStatus unknownNCT04989322Phase 2
- Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)Active, not recruitingNCT04938817Phase 1/2
- Study of TACE Combined With Lenvatinib to Prevent Postoperative Recurrence in Patients With MVI Positive HCCStatus unknownNCT04911959Phase 1/2
- Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic CancerActive, not recruitingNCT04887805Phase 2
- Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue SarcomaActive, not recruitingNCT04784247Phase 2
- Systemic Chemotherapy, Lenvatinib Plus Sintilimab for ICC With Distant MetastasisStatus unknownNCT04769908Phase 2
- An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric CancerActive, not recruitingNCT04745988Phase 2
- Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)Status unknownNCT04741165Phase 2
- Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid CancerWithdrawnNCT04731740Phase 2
- Pembrolizumab And Lenvatinib In Leptomeningeal MetastasesTerminatedNCT04729348Phase 2
- Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIentsCompletedNCT04710628Phase 2
- Trial of Lenvatinib Plus PembrolizumAb in Recurrent Gynecological Clear Cell Adenocarcinomas (LARA)Status unknownNCT04699071Phase 2
- Lenvatinib in Patients With Previously Treated Advanced Biliary Tract CancerCompletedNCT04656249Phase 2
- Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular CarcinomaCompletedNCT04642547Not applicable
- Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)CompletedNCT04626518Phase 1/2
- Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)CompletedNCT04626479Phase 1/2
- Lenvatinib and Pembrolizumab in Resectable Mucosal MelanomaStatus unknownNCT04622566Phase 2
- HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTTCompletedNCT04618367Not applicable
- A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)Active, not recruitingNCT04586231Phase 3
- Pembrolizumab in Combination With Lenvatinib in Patients With Advanced Biliary Tract CarcinomaCompletedNCT04550624Phase 2
- The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular CarcinomaCompletedNCT04542837Phase 2